Description: AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names. The company offers products in the areas of cardiovascular, renal, metabolic, oncology, antidiabetic, respiratory, inflammation, and autoimmunity diseases. It also provides clinical trial services. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Home Page: www.astrazeneca.com/india
Manyata Embassy Business Park
Bengaluru,
560045
India
Phone:
91 80 6774 8000
Officers
| Name | Title |
|---|---|
| Mr. Gagandeep Singh Bedi | MD, Country Pres & Exec. Director |
| Mr. Rajesh Marwaha | CFO & Exec. Director |
| Mr. Pratap Rudra Bhuvanagiri | Company Sec., Legal Counsel & Compliance Officer |
| Ms. Smita Saha | VP of HR |
| Mr. Richard Cheeseman | Head of Engineering & Facilities |
| Dr. José Baselga | Exec. VP, Pres of R&D Oncology |
| Mr. Vimlesh Maheshwari | Fin. Controller |
| Dr. K. R. Premnath Shenoy | Director of Regulatory |
| Mr. Ramesh Kadaba Venkatapathi | Director of Quality Assurance & Technical Services |
| Dr. Paurus Mehelli Irani | Global Medical Affairs Leader - Infection |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 154.2267 |
| Price-to-Book MRQ: | 29.3481 |
| Price-to-Sales TTM: | 13.0341 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1325 |